These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33387087)

  • 1. TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway.
    Tan G; Xie B; Yu N; Huang J; Zhang B; Lin F; Li H
    Int J Clin Oncol; 2021 Mar; 26(3):532-542. PubMed ID: 33387087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.
    Zheng SS; Wu JF; Wu WX; Hu JW; Zhang D; Huang C; Zhang BH
    Hepatol Int; 2024 Oct; 18(5):1499-1515. PubMed ID: 38769286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
    He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
    J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Y-box binding protein 1 augments sorafenib resistance
    Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ
    World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma.
    Dai J; Huang Q; Niu K; Wang B; Li Y; Dai C; Chen Z; Tao K; Dai J
    Cancer Med; 2018 Nov; 7(11):5691-5703. PubMed ID: 30311444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sestrin 2(SESN2) promotes primary resistance to sorafenib by activating AKT in hepatocellular carcinoma cells].
    Dai J; Niu K; Wang B; Li Y; Xia C; Tao K; Dai J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 May; 34(5):427-433. PubMed ID: 30043734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.
    Yu C; Chen S; Guo Y; Sun C
    Theranostics; 2018; 8(12):3224-3236. PubMed ID: 29930725
    [No Abstract]   [Full Text] [Related]  

  • 13. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
    Wu J; Chai H; Li F; Ren Q; Gu Y
    Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
    Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
    Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
    Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
    Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.
    Guo XL; Wang HB; Yong JK; Zhong J; Li QH
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
    Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.